Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

The current standard of care for patients with esophageal or GEJ cancer following neoadjuvant CRT and tumor resection is surveillance.